UK Markets close in 41 mins

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
55.50+0.01 (+0.02%)
As of 03:29PM BST. Market open.
Currency in CHF

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.07
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 356.10
52-week low 355.50
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 515M
Implied shares outstanding 6N/A
Float 88.88M
% held by insiders 147.28%
% held by institutions 111.80%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 31.85
Trailing annual dividend yield 33.33%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Jun 2022


Profit margin 45.14%
Operating margin (ttm)24.57%

Management effectiveness

Return on assets (ttm)1.81%
Return on equity (ttm)8.40%

Income statement

Revenue (ttm)78.17M
Revenue per share (ttm)4.36
Quarterly revenue growth (yoy)46.10%
Gross profit (ttm)32.1M
Net income avi to common (ttm)35.28M
Diluted EPS (ttm)-0.60
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)218.96M
Total cash per share (mrq)13.36
Total debt (mrq)171.83M
Total debt/equity (mrq)36.62
Current ratio (mrq)11.44
Book value per share (mrq)27.72

Cash flow statement

Operating cash flow (ttm)15.5M
Levered free cash flow (ttm)-1.88M